Inari Medical: Clot Warriors—Changing the Paradigm in DVT and Pulmonary Embolism



Inari Medical is a 2020 success story. The company was one of the first medtech companies to IPO during the pandemic. As part of the new Medtech Talk Digital Discussion Series, host Geoff Pardo had a chance to conduct a panel interview with four members of the Inari management team: Bill Hoffman, CEO; Drew Hykes, CCO; Thomas Tu, MD, CMO; and Tara Dunn, Vice President of Clinical Affairs and Market Development. The team discussed their unique culture, strong mission, early success, sales strategy and many other topics, including advice from Bill to other entrepreneurs who are considering going public, reflections from Tom on the transition from being a physician to the business world, benchmarking from Drew on how this experience compares to other ventures he has been in, and comparisons from Tara on the difference between working for a big company vs. a smaller company. Tune in now to hear from one of medtech’s most promising companies!

Podcast Guest


Bill Hoffman


Inari Medical, Inc.

Bill has focused on early stage companies with novel devices in new markets. Prior to Inari Medical, Bill served as CEO of Visualase, Inc., which developed and sold lasers for minimally invasive neurosurgery. The company was acquired by Medtronic for $105M in July, 2014, having raised less than $10m in equity funding. Prior to Visualase, Bill was Vice President of Sales at FoxHollow, Inc., helping to build a commercial team and revenue ramp that led to a successful IPO in 2004 and an acquisition by EV3 in 2007. Bill’s first early stage med tech experience was as head of sales at RITA Medical Systems, an interventional oncology company that enjoyed a successful IPO in 2000. He spent the early part of his career in various sales roles at Ethicon and Medtronic.


Drew Hykes


Inari Medical, Inc.

Drew is a proven medical device operating executive with broad functional, geographic and sector experience. From 2012-2016 Drew served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market. Sequent was acquired by Terumo Corporation in July 2016 for $380 million. Prior to Sequent, Drew spent 11 years at Medtronic. His roles at Medtronic included the VP of Marketing for the AF Solutions business, VP of Clinical and Regulatory for the AF Solutions business and Director of Investor Relations. Drew also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. He earned a B.B.A. in Finance from the University of Wisconsin and an MBA from Harvard Business School.


Thomas Tu, MD


Inari Medical, Inc.

Dr. Thomas Tu joins Inari Medical after practicing Interventional Cardiology for 16 years. He is a graduate of Harvard Medical School and completed residency at Massachusetts General Hospital. He was trained in Interventional Cardiology, Peripheral Vascular Intervention, and Structural Heart Disease at Beth Israel Deaconess Medical Center. Most recently, he was the Cath Lab director and leader of the Pulmonary Embolism, complex PCI, and TAVR programs at Baptist Health Louisville. Dr. Tu helped develop the early phase technology that allowed Inari Medical to optimize patient outcomes. He also served as the presenter for the FLARE IDE trial of the Inari FlowTriever Retrieval/Aspiration System. This study led to FDA 510 (k) clearance for treatment of pulmonary embolism, the first thrombectomy device cleared for that indication.


Tara Dunn

Vice President of Clinical Affairs and Market Development

Inari Medical, Inc.

Tara has extensive multi-functional medical device experience across a range of start-ups and larger organizations. Her most recent role was as the Venous Business Segment Leader at Volcano Corporation, acquired by Philips in 2015. Tara’s venous business experienced explosive triple digit growth in her time at the helm. Prior to Philips Volcano, she worked at Medtronic in Corporate Development where she participated in numerous transactions including the ~$816M acquisition of Kanghui Holdings in China and the divestiture of its Physio-Control business unit to Bain Capital for $487M. Tara also worked as a project leader at a healthcare strategy consulting firm called Health Advances and as Manager, Clinical and Regulatory Affairs at InfraReDx. She earned an A.B. in Biology from Harvard University, a M.S. in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and a M.B.A from Harvard Business School. Tara was a member of the National Championship winning ice hockey team and Ivy league championship team in softball while at Harvard. She also went on to compete in the National Women’s Hockey League (NWHL) for two seasons.

Do You Have


If you’d like to be considered as a guest on a future episode of the Medtech Talk Podcast, please complete the application today.

Meet Our Host

Geoff Pardo


Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.



Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!